Background: The superiority of combination therapy for carbapenem-resistant Gram-
negative bacilli (CR-GNB) remains controversial. In vitro models may predict the efficacy of …

The emergence of resistant to carbapenems Gram-negative bacteria (CR GNB) has severely
challenged antimicrobial therapy. Many CR GNB isolates are only susceptible to …

Objectives To explore contemporary antibiotic management of infections caused by
carbapenem-resistant Gram-negative bacteria in hospitals. Methods Cross-sectional …

Clinicians may use ceftazidime/avibactam in combination with other active agents to treat
infections due to carbapenem-resistant organisms, although no conclusive data support this …

Carbapenem-resistant Gram-negative bacteria (CR-GNB) represent an increasing hazard in
healthcare settings. A central question concerning the treatment of invasive infections …

ABSTRACT Multidrug-resistant (MDR) Gram-negative organisms are a major health concern
due to lack of effective therapy. Emergence of resistance to newer agents like ceftazidime …

Background Rates of colonization and infection with carbapenem-resistant Gram-negative
pathogens are on the rise, particularly in southeastern European countries, and this is …

Infections caused by carbapenemase-producing, multidrug-resistant (MDR), or extensively
drug-resistant (XDR) Gram-negative bacteria constitute a major therapeutic challenge …

Our objective was to examine the evidence of in vitro synergy of polymyxin-carbapenem
combination therapy against Gram-negative bacteria (GNB). A systematic review and meta …

Introduction Pathogen-focused, randomized, controlled trials (PF-RCT) are important in the
fight against carbapenem-resistant (CR) Gram-negative infections. Some recently approved …